卡培他滨单药或联合奥沙利铂同步放化疗对晚期直肠癌的临床疗效研究

Clinical research of capecitabine monotherapy or in combination with oxaliplatin concurrent chemoradiotherapy on patients with advanced colorectal cancer

目的观察卡培他滨单药或联合奥沙利铂同步放化疗对晚期直肠癌的临床疗效。方法 52例晚期直肠癌患者随机分为试验组和对照组,每组26例。2组均采取6 m V的X射线进行照射,每周5次,共5周。放疗的同时,对照组用卡培他滨单药化疗,每天2次,总剂量为1500~1700 mg·m^(-2)。试验组静脉滴注奥沙利铂总剂量为50~75 mg·m^(-2),每周1次,卡培他滨每天2次,总剂量为1200~1550 mg·m^(-2),每个周期均为35 d,2组均治疗3个周期。观察2组患者的临床疗效、生活质量改善及不良反应发生情况。结果治疗后,试验组患者客观缓解率(76.93%)显著高于对照组(42.31%,P<0.05);试验组生活质量的改善情况显著优于对照组(P<0.05);试验组患者不良反应率显著低于对照组(P<0.05)。结论卡培他滨联合奥沙利铂同步放化疗治疗晚期直肠癌患者疗效较好,不良反应相对较低,可改善患者的生活质量,有利于患者预后。

Objective To analyze the clinical efficacy of capecitabine monotherapy or in combination with oxaliplatin concurrent chemoradiotherapy on patients with advanced colorectal cancer. Methods Fifty-two patients with advanced colorectal cancer were randomly divided into treatment group and control group,26 cases in each group. Two groups were all taken 6 m V X- ray irradiation,5 times a week,totally five weeks. On the same time,control group was given capecitabine,twice a day,with the total dose of 1500- 1700 mg·m^-2. Treatment group was given oxaliplatin total dose of 50- 75 mg·m^-2,once a week,and capecitabine,twice a day,with the total dose of 1200- 1550 mg·m^-2.And 35 d a course,all patients were given three courses treatment. Clinical efficacy,improvement in quality of life and adverse drug reactions of the two groups were observed. Results After treatment,the objective response rate in treatment group（ 76. 93%） was significantly higher than that in control group（ 42. 31%,P〈0. 05）; the quality of life in treatment group was significantly better than that in control group（ P〈0. 05）.The incidence rate adverse reactions in treatment group were significantly lower than that in control group（ P〈0. 05）. Conclusion Capecitabine combined with oxaliplatin for the treatment of patients with advanced colorectal cancer had a good clinical efficacy,low incidence of adversereactions,which can improve the quality of life.